BACKGROUND: The primary cause for late failure of vascularized allografts is chronic rejection (CR) characterized by transplant vascular sclerosis (TVS). Cytomegalovirus (CMV) infection accelerates TVS and CR by unclear mechanisms involving direct effects of CMV, indirect effects of the recipient's immune response to CMV, or interactions between CMV and the recipient's alloreactivity. This study examined the role of CMV and the alloreactive response in the development of TVS using bone marrow chimerism (BMC) in rat small bowel (SB) and heart transplantation models. METHODS: Fisher 344 (F344) rat heart or SB grafts were transplanted into F344/Lewis bone marrow chimera. F344 heart or SB grafts transplanted into Lewis recipients (low-dose cyclosporine) were positive controls for the development of TVS. Lewis heart or SB grafts transplanted into Lewis recipients (+/-cyclosporine) were transplantation controls. The effect of rat CMV (RCMV) (5x105 plaque-forming units) on TVS (neointimal index, NI) and graft survival was studied in these groups. RCMV infection was assessed by serologic analysis and quantitative polymerase chain reaction techniques (TaqMan). RESULTS: RCMV infection accelerated the time to graft CR (SB 70-38 days; hearts 90-45 days) and increased the severity of TVS in both the SB allografts (day 38, NI=27 vs. 52) and the heart allografts (day 45, NI=43 vs. 83). Grafts from CMV-infected syngeneic recipients failed to develop TVS and CR. Donor-specific tolerance induced by BMC prevented allograft TVS and CR in both transplant models. In contrast to naïve Lewis recipients, RMCV infection failed to cause allograft TVS and CR in bone marrow (BM) chimeras. CONCLUSIONS: The events in CMV-induced acceleration of TVS involve a crucial interplay between CMV infection and the recipient's alloreactive immune response.
BACKGROUND: The primary cause for late failure of vascularized allografts is chronic rejection (CR) characterized by transplant vascular sclerosis (TVS). Cytomegalovirus (CMV) infection accelerates TVS and CR by unclear mechanisms involving direct effects of CMV, indirect effects of the recipient's immune response to CMV, or interactions between CMV and the recipient's alloreactivity. This study examined the role of CMV and the alloreactive response in the development of TVS using bone marrow chimerism (BMC) in ratsmall bowel (SB) and heart transplantation models. METHODS: Fisher 344 (F344) rat heart or SB grafts were transplanted into F344/Lewis bone marrow chimera. F344 heart or SB grafts transplanted into Lewis recipients (low-dose cyclosporine) were positive controls for the development of TVS. Lewis heart or SB grafts transplanted into Lewis recipients (+/-cyclosporine) were transplantation controls. The effect of rat CMV (RCMV) (5x105 plaque-forming units) on TVS (neointimal index, NI) and graft survival was studied in these groups. RCMV infection was assessed by serologic analysis and quantitative polymerase chain reaction techniques (TaqMan). RESULTS:RCMV infection accelerated the time to graft CR (SB 70-38 days; hearts 90-45 days) and increased the severity of TVS in both the SB allografts (day 38, NI=27 vs. 52) and the heart allografts (day 45, NI=43 vs. 83). Grafts from CMV-infected syngeneic recipients failed to develop TVS and CR. Donor-specific tolerance induced by BMC prevented allograft TVS and CR in both transplant models. In contrast to naïve Lewis recipients, RMCVinfection failed to cause allograft TVS and CR in bone marrow (BM) chimeras. CONCLUSIONS: The events in CMV-induced acceleration of TVS involve a crucial interplay between CMV infection and the recipient's alloreactive immune response.
Authors: Daniel N Streblow; Koen W R van Cleef; Craig N Kreklywich; Christine Meyer; Patricia Smith; Victor Defilippis; Finn Grey; Klaus Früh; Robert Searles; Cathrien Bruggeman; Cornelis Vink; Jay A Nelson; Susan L Orloff Journal: J Virol Date: 2007-01-24 Impact factor: 5.103
Authors: S L Orloff; Y-K Hwee; C Kreklywich; T F Andoh; E Hart; P A Smith; I Messaoudi; D N Streblow Journal: Am J Transplant Date: 2011-01 Impact factor: 8.086
Authors: Christine Meyer; Finn Grey; Craig N Kreklywich; Takeshi F Andoh; Rebecca S Tirabassi; Susan L Orloff; Daniel N Streblow Journal: J Virol Date: 2010-10-27 Impact factor: 5.103
Authors: Jennifer Vomaske; Michael Denton; Craig Kreklywich; Takeshi Andoh; Jessica M Osborn; Daniel Chen; Ilhem Messaoudi; Susan L Orloff; Daniel N Streblow Journal: J Virol Date: 2012-08-22 Impact factor: 5.103
Authors: Jerome Dumortier; Daniel N Streblow; Ashlee V Moses; Jon M Jacobs; Craig N Kreklywich; David Camp; Richard D Smith; Susan L Orloff; Jay A Nelson Journal: J Virol Date: 2008-04-30 Impact factor: 5.103
Authors: Carmen C Baca Jones; Craig N Kreklywich; Ilhem Messaoudi; Jennifer Vomaske; Erin McCartney; Susan L Orloff; Jay A Nelson; Daniel N Streblow Journal: Virology Date: 2009-04-05 Impact factor: 3.616
Authors: Piotr Religa; Monika K Grudzinska; Krzysztof Bojakowski; Joanna Soin; Jerzy Nozynski; Michal Zakliczynski; Zbigniew Gaciong; Marian Zembala; Cecilia Söderberg-Nauclér Journal: PLoS One Date: 2009-01-14 Impact factor: 3.240